Differential diagnosis of idiopathic inflammatory myopathies

Current Rheumatology Reports

Volumn 8, Issue 3, 2006, Pages 178-187

  Baer, Alan N ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COLCHICINE; CORTICOSTEROID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; MUSCLE ENZYME; NEUROMUSCULAR BLOCKING AGENT; PENICILLAMINE; PROCAINAMIDE; ZIDOVUDINE; BIOLOGICAL MARKER;

ARTICLE; BECKER MUSCULAR DYSTROPHY; CONNECTIVE TISSUE DISEASE; DERMATITIS; DERMATOMYOSITIS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DUCHENNE MUSCULAR DYSTROPHY; ENDOCRINE DISEASE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; INFECTION; LIMB GIRDLE MUSCULAR DYSTROPHY; METABOLIC DISORDER; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOPATHY; MYOSITIS; MYOTONIC DYSTROPHY; NEUROLOGIC DISEASE; NEUROPATHY; POLYMYOSITIS; BIOPSY; ENZYMOLOGY; GENETIC PROCEDURES; METABOLISM; PATHOLOGY; REVIEW; SKELETAL MUSCLE;

BIOLOGICAL MARKERS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; GENETIC TECHNIQUES; HUMANS; MUSCLE, SKELETAL; MYOSITIS;

EID: 33747613048     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-996-0023-5     Document Type: Article

References (52)

1. Dalakas MC: Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:779-798. An excellent summary of the key histopathologic features of dermatomyositis, polymyositis, and IBM. The author does not adequately address the classification of myositis patients who lack the specific histopathologic features of these three forms of IIM.
2. Zampieri S, Ghirardello A, Iaccarino L, et al.: Anti-Jo-1 antibodies. Autoimmunity 2005, 38:73-78.
3. van der Meulen MF, Bronner IM, Hoogendijk JE, et al.: Polymyositis: an overdiagnosed entity. Neurology 2003, 61:316-321. In this retrospective follow-up study of 165 patients with autoimmune myositis, polymyositis was the least common form when defined pathologically by the presence of lymphocytes surrounding and preferably invading non-necrotic muscle fibers. Most of the patients had a myositis with strictly perimysial/perivascular infiltrates or a non-inflammatory necrotizing myopathy that could not be further categorized.
4. Tsokos GC, Moutsopoulos HM, Steinberg AD: Muscle involvement in systemic lupus erythematosus. JAMA 1981, 246:766-768.
5. Ghirardello A, Zampieri S, Iaccarino L, et al.: Anti-Mi-2 antibodies. Autoimmunity 2005, 38:79-83.
6. Lacomis D: Electrodiagnostic approach to the patient with suspected myopathy. Neurol Clin 2002, 20:587-603. A detailed summary of the utility of electrodiagnostic testing in the differential diagnosis of myopathies.
7. Luciano CA, Dalakas MC: Inclusion body myositis: no evidence for a neurogenic component. Neurology 1997, 48:29-33.
8. Dion E, Cherin P, Payan C, et al.: Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002, 29:1897-1906. A study of the MRI abnormalities in the thigh muscles of 25 polymyositis and 25 IBM patients. The pattern of abnormalities was different, allowing for differentiation of the two disorders.
9. Lam WW, Chan H, Chan YL, et al.: MR imaging in amyopathic dermatomyositis. Acta Radiol 1999, 40:69-72.
10. Griggs RC, Askanas V, DiMauro S, et al.: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
11. Troyanov Y, Targoff IN, Tremblay JL, et al.: Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005, 84:231-249. The authors test two modifications of the Bohan and Peter criteria that are based on the presence of clinical features and/or autoantibodies that overlap with other connective tissue diseases. Most of the patients in their cohort of IIM have "overlap myositis".
12. Miller F, Rider L, Plotz P, et al.: Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003, 362:1762-1763. A letter to the editor written by myositis experts voicing concern about the adoption of pathology-driven categorization of the inflammatory myopathies.
13. van der Pas J, Hengstman GJ, ter Laak HJ, et al.: Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004, 75:136-139. Major histocompatibility complex class I staining has utility in differentiating the IIM from other forms of myopathy.
14. Greenberg SA, Walsh RJ: Molecular diagnosis of inheritable neuromuscular disorders. Part II: application of genetic testing in neuromuscular disease. Muscle Nerve 2005, 31:431-451. An update on molecular testing that is now available to diagnose inheritable neuromuscular disorders, including many forms of muscular dystrophy and metabolic myopathy.
15. Pogue R, Anderson LV, Pyle A, et al.: Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2001, 11:80-87. An approach to the molecular diagnosis of the autosomal recessive limb-girdle muscular dystrophies is presented.
16. Lundberg I, Nennesmo I, Hedfors E: A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum 1992, 22:127-138.
17. Koffman BM, Rugiero M, Dalakas MC: Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998, 21:115-117.
18. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A: Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998, 50:764-767.
19. Bronner IM, Hoogendijk JE, Wintzen AR, et al.: Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003, 250:480-485. Eight patients are described with symmetrical muscle weakness and marked CK elevation whose muscle biopsies showed a necrotizing myopathy without mononuclear cell infiltrates.
20. Emslie-Smith AM, Engel AG: Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991, 41:936-939.
21. Kalovidouris AE, Stoesz E, Muller J, et al.: Relationships between clinical features and distribution of mononuclear cells in muscle of patients with polymyositis. J Rheumatol 1988, 15:1401-1406.
22. Amato AA, Griggs RC: Unicorns, dragons, polymyositis, and other mythological beasts. Neurology 2003, 61:288-289. In this editorial, two neurologists present their arguments in support of the concept that "true polymyositis" is rare and the least common form of IIM.
23. Christopher-Stine L, Plotz PH: Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 2004, 18:331-344.
24. Hilton-Jones D: Diagnosis and treatment of inflammatory muscle diseases. J Neurol Neurosurg Psychiatry 2003, 74(Suppl II):ii25-ii31.
25. Emery AE: The muscular dystrophies. BMJ 1998, 317:991-995.
26. Kissel JT: Misunderstandings, misperceptions, and mistakes in the management of the inflammatory myopathies. Semin Neurol 2002, 22:41-51. An expert clinician describes common mistakes made in the diagnosis of the IIM.
27. Gallardo E, Rojas-Garcia R, de Luna N, et al.: Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138. Inflammatory infiltrates were present in the muscle biopsies of nine of 13 patients with dysferlin myopathy; the authors characterize these infiltrates with immunohistochemistry.
28. Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
29. Arahata K, Ishihara T, Fukunaga H, et al.: Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve 1995, 2:S56-S66.
30. Argov Z, Sadeh M, Mazor K, et al.: Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 2000, 123:1229-1237. An analysis of the clinical and genetic features of 29 patients with dysferlinopathy from a cluster of 12 Jewish families of Libyan origin.
31. Confalonieri P, Oliva L, Andreetta F, et al.: Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003, 142:130-136.
32. Ricker K: Myotonic dystrophy and proximal myotonic myophathy. J Neurol 1999, 246:334-338.
33. Wortmann RL, DiMauro S: Differentiating idiopathic inflammatory myopathies from metabolic myopathies. Rheum Dis Clin N Am 2002, 28:759-778. The authors review the clinical, laboratory, and genetic features that distinguish the IIM from the metabolic myopathies.
34. DiMauro S, Hays AP, Tsujino S: Nonlysosomal glycogenoses. In Myology: Basic and Clinical. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw-Hill; 2004:1535-1558.
35. DiMauro S, Lamperti C: Muscle glycogenoses. Muscle Nerve 2001, 24:984-999. A review of the clinical and laboratory features of the 11 hereditary disorders of glycogen metabolism.
36. Danon MJ, Servidei S, DiMauro S, Vora S: Late-onset muscle phosphofructokinase deficiency. Neurology 1988, 38:956-960.
37. Trend PS, Wiles CM, Spencer GT, et al.: Acid maltase deficiency in adults. Diagnosis and management in five cases. Brain 1985, 108:845-860.
38. Cornelio F, Bresolin N, Singer PA, et al.: Clinical varieties of neuromuscular disease in debrancher deficiency. Arch Neurol 1984, 41:1027-1032.
39. Johnston W, Karpati G, Carpenter S, et al.: Late-onset mitochondrial myopathy. Ann Neurol 1995, 37:16-23.
40. Kiechl S, Kohlendorfer U, Thaler C, et al.: Different clinical aspects of debrancher deficiency myopathy. J Neurol Neurosurg Psychiatry 1999, 67:364-368.
41. DiMauro S, Schon EA: Mitochondrial respiratory-chain diseases. N Engl J Med 2003, 348:2656-2668. An excellent review of mitochondrial diseases and their genetics.
42. Nardin RA, Johns DR: Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001, 24:170-191. A comprehensive review of the neuromuscular manifestations of mitochondrial disease.
43. Sciacco M, Prelle A, Comi GP, et al.: Retrospective study of a large population of patients affected with mitochondrial disorders: clinical, morphological and molecular genetic evaluation. J Neurol 2001, 248:778-788. The authors correlate genotype with phenotype in 207 patients affected with mitochondrial disorders. This is an excellent summary of the clinical, laboratory, and histologic features of a large cohort of patients with mitochondrial myopathies.
44. Taylor RW, Schaefer AM, Barron MJ, et al.: The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004, 14:237-245. The authors provide a step-by-step approach to the clinical and laboratory diagnosis of mitochondrial myopathies.
45. Khaleeli AA, Griffith DG, Edwards RHT: The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle. Clin Endocrinol 1983, 19:365-376.
46. Lacomis D, Zochodne DW, Bird SJ: Critical illness myopathy. Muscle Nerve 2000, 23:1785-1788.
47. Kallen PS, Louie JS, Nies KM, Bayer AS: Infectious myositis and related syndromes. Semin Arthritis Rheum 1982, 11:421-439.
48. Cuturic M, Hayat GR, Vogler CA, Velasques A: Toxoplasmic polymyositis revisited: case report and review of the literature. Neuromusc Dis 1997, 7:390-396.
49. Walji S, Rubenstein J, Shannon P, Carette S: Disseminated pyomyositis mimicking idiopathic inflammatory myopathy. J Rheumatol 2005, 32:184-187.
50. Reveille JD: The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000, 30:147-166.
51. Maselli RA, Richman DP, Wollmann RL: Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 1991, 41:1497-1504.
52. Sieb JP: Myopathies due to drugs, toxins, and nutritional deficiency. In Myology: Basic and Clinical. Edited by Engel A, Franzini-Armstrong L. New York: McGraw-Hill; 2004:1693-1712.